Study guide

4.3 Pulmonary Disorders

North American Pharmacist Licensure Examination NAPLEX

Track your progress as you read

Finished sections get a check mark.

1 Introduction & NAPLEX Exam Overview

1.1 NAPLEX Exam Facts & Logistics 1.2 Eligibility & the Licensure Path 1.3 Competency Blueprint & Study Strategy

2 Foundational Knowledge for Pharmacy Practice

2.1 Pharmacology, Mechanisms & Drug Classes 2.2 Pharmacokinetics & Pharmacodynamics 2.3 Pharmaceutical Calculations & Literature Evaluation

3 The Medication Use Process

3.1 Prescription Processing & Dispensing Accuracy 3.2 Sterile & Non-Sterile Compounding 3.3 Medication Safety & Pharmacovigilance 3.4 Immunization Services & Documentation

4 Person-Centered Care: Cardiometabolic, Pulmonary & Renal

4.1 Cardiovascular Disorders 4.2 Diabetes, Endocrine & Renal 4.3 Pulmonary Disorders

5 Person-Centered Care: ID, Neuro-Psych, GI, Oncology & Special Populations

5.1 Infectious Disease 5.2 Neurology, Psychiatry & Gastroenterology 5.3 Oncology, Heme & Special Populations 5.4 Patient Assessment, Self-Care & Point-of-Care Testing

6 Professional Practice, Management & Final Review

6.1 Professional Practice 6.2 Pharmacy Management & Leadership 6.3 High-Yield Review & 6-Hour Test Strategy

4.3 Pulmonary Disorders

Key Takeaways Explain This Topic AI

Asthma management is stepwise: inhaled corticosteroid (ICS)-containing therapy is the controller foundation, and short-acting beta-agonist (SABA) reliever-only treatment without an inhaled corticosteroid is no longer preferred for most patients.

Chronic obstructive pulmonary disease (COPD) maintenance therapy is built on long-acting bronchodilators (LABA and/or long-acting muscarinic antagonist, LAMA), with inhaled corticosteroids added in selected patients such as those with frequent exacerbations or eosinophilia.

Inhaler technique and device selection are tested directly; metered-dose inhalers (MDIs), dry powder inhalers (DPIs), and soft-mist inhalers each require different inhalation maneuvers, and DPIs require a forceful inhalation.

Asthma and COPD exacerbations are commonly managed with systemic corticosteroids and intensified bronchodilation; COPD exacerbations with increased sputum purulence often warrant antibiotics.

Smoking cessation pharmacotherapy includes nicotine replacement therapy, varenicline, and bupropion, paired with behavioral support to maximize quit rates.

Last updated: June 2026

Pulmonary Therapeutics and Patient-Centered Care

Respiratory disease is high-yield on the NAPLEX because correct therapy depends on disease type, control or exacerbation status, and the patient's ability to use a device correctly. Selecting the right drug is only half the answer; the exam frequently tests whether you can also choose and teach the right inhaler.

Asthma

Asthma is a chronic inflammatory airway disorder causing reversible bronchoconstriction, wheeze, cough, and dyspnea. Two therapeutic roles must be distinguished: controller therapy that reduces airway inflammation and prevents exacerbations, and reliever therapy for acute symptoms.

Stepwise Principles

Modern asthma care is stepwise : therapy is stepped up if control is inadequate and stepped down once control is sustained. The central change in current guideline thinking is that inhaled corticosteroid (ICS)-containing therapy is the foundation of treatment . Using a short-acting beta-agonist (SABA) alone, with no inhaled corticosteroid, is no longer preferred for most patients because it does not treat the underlying inflammation that drives exacerbations.

Drug class Examples Role Monitoring / counseling

Inhaled corticosteroids (ICS) budesonide, fluticasone, beclomethasone Controller foundation Rinse mouth after use to reduce oral candidiasis; assess control and technique

Long-acting beta-agonists (LABA) formoterol, salmeterol Add-on controller (always with an ICS in asthma) Never use a LABA without an ICS in asthma

Long-acting muscarinic antagonist (LAMA) tiotropium Add-on for inadequate control Counsel on device technique; dry mouth

  • Leukotriene receptor antagonist montelukast Alternative/add-on controller Counsel on neuropsychiatric warnings
  • Short-acting beta-agonist (SABA) albuterol Reliever for acute symptoms Frequent use signals poor control
  • Biologics targeted monoclonal antibodies Severe, specific phenotypes Specialist-directed; phenotype-guided

Counseling pearl: Frequent SABA use, nighttime symptoms, or rescue inhaler refills more than expected indicate poor control and should trigger a step-up review of adherence and inhaler technique before escalating drug therapy.

Chronic Obstructive Pulmonary Disease (COPD)

COPD is a progressive disorder of persistent airflow limitation, usually from long-term noxious exposure such as tobacco smoke. Unlike asthma, the maintenance backbone is long-acting bronchodilation , not inhaled corticosteroids.

Maintenance Strategy

LAMA and/or LABA long-acting bronchodilators are the maintenance foundation, used alone or in dual combination based on symptom burden and exacerbation history.

Inhaled corticosteroids are added in selected patients, such as those with frequent exacerbations or higher blood eosinophils, balanced against an increased pneumonia risk.

SABA or short-acting muscarinic antagonist provides as-needed symptom relief.

Non-pharmacologic care including smoking cessation, vaccination, and pulmonary rehabilitation is essential and frequently the best answer in a person-centered question.

Inhaler Technique and Device Selection

Device errors are a leading cause of "treatment failure" that is actually a technique problem. The NAPLEX tests recognition of the correct maneuver for each device class.

Device Inhalation maneuver Key counseling point

Metered-dose inhaler (MDI) Slow, deep inhalation with actuation coordination A spacer/valved holding chamber improves delivery and reduces coordination errors

Dry powder inhaler (DPI) Quick, forceful, deep inhalation Do not exhale into the device; humidity can clump powder

Soft-mist inhaler Slow, steady inhalation Requires priming/preparation per device instructions

Nebulizer Normal tidal breathing through mouthpiece/mask Useful when a patient cannot coordinate handheld devices

High-yield contrast: An MDI requires a slow, deep breath , whereas a DPI requires a quick, forceful breath because the patient's own inspiratory effort disaggregates the powder. Choosing a device the patient can physically use correctly is a person-centered decision the exam rewards.

Exacerbation Management

An exacerbation is an acute worsening of respiratory symptoms beyond normal day-to-day variation.

Asthma exacerbation: intensified short-acting bronchodilation and a course of systemic corticosteroids for moderate-to-severe events, with oxygen as needed and reassessment of controller therapy and technique afterward.

COPD exacerbation: intensified bronchodilation and systemic corticosteroids; antibiotics are added when there are signs of a likely bacterial cause , such as increased sputum purulence with increased volume or dyspnea. After recovery, review maintenance therapy and adherence.

Smoking Cessation

Tobacco cessation is the single most impactful intervention in COPD and a recurring person-centered counseling topic. Pharmacotherapy combined with behavioral support produces the best quit rates.

Therapy Examples Key counseling

Nicotine replacement therapy (NRT) patch (long-acting) plus gum or lozenge (short-acting) Combining a long-acting patch with a short-acting form improves success

  • Varenicline varenicline Take with food; counsel to report mood or behavior changes
  • Bupropion sustained-release bupropion Avoid with seizure disorder; can be combined with NRT

Always pair pharmacotherapy with counseling, set a quit date, and arrange follow-up; the most complete answer in a cessation case usually includes both a medication and behavioral support.

Allergic Rhinitis and Adjacent Airway Conditions

Allergic rhinitis frequently coexists with asthma and is a common counseling topic. Intranasal corticosteroids (fluticasone, mometasone, budesonide) are the most effective single class for persistent symptoms; second-generation oral antihistamines (loratadine, cetirizine, fexofenadine) are preferred over sedating first-generation agents for daytime use. Counsel patients that intranasal steroids require consistent daily use for full benefit and to aim the spray slightly away from the septum to reduce epistaxis.

Oral and intranasal decongestants (pseudoephedrine, oxymetazoline) provide short-term relief but carry cautions: pseudoephedrine can raise blood pressure and is restricted at the counter, and topical oxymetazoline causes rebound congestion (rhinitis medicamentosa) if used beyond about three days.

Vaccination and Non-Pharmacologic Care in Respiratory Disease

For both asthma and COPD, the most complete person-centered answer often pairs drug therapy with prevention. Annual influenza vaccination , age- and risk-appropriate pneumococcal vaccination , and COVID-19 and RSV vaccination per current recommendations reduce exacerbations and hospitalizations. Pulmonary rehabilitation, action plans, and trigger avoidance further lower risk.

  • Intervention Why it matters in obstructive lung disease
  • Smoking cessation The single most effective step to slow COPD progression
  • Influenza vaccine (annual) Reduces exacerbations and respiratory hospitalizations
  • Pneumococcal vaccine Lowers invasive pneumococcal disease risk
  • Inhaler technique review Corrects "treatment failure" that is really a device error
  • Written action plan Helps patients self-manage early symptom changes

Exam cue: When a stable COPD or asthma vignette asks for the best additional intervention and the patient is a smoker or unvaccinated, the highest-value answer is often cessation support or an indicated vaccine rather than escalating inhaled drug therapy.